drugset / Trial / NCT00387270
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.
Timeline
- Start
- 2006-10
- Primary completion
- 2007-03
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latrepirdine | Small molecule | 10 mg | — |
| Subject | Latrepirdine | Small molecule | 20 mg | — |